دورية أكاديمية
Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.
| العنوان: | Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells. |
|---|---|
| المؤلفون: | van 't Erve I; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Medina JE; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Leal A; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Papp E; Personal Genome Diagnostics, Baltimore, Maryland., Phallen J; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Adleff V; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Chiao EJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Arun AS; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Bolhuis K; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Simmons JK; Personal Genome Diagnostics, Baltimore, Maryland., Karandikar A; Personal Genome Diagnostics, Baltimore, Maryland., Valkenburg KC; Personal Genome Diagnostics, Baltimore, Maryland., Sausen M; Personal Genome Diagnostics, Baltimore, Maryland., Angiuoli SV; Personal Genome Diagnostics, Baltimore, Maryland., Scharpf RB; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Punt CJA; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands., Meijer GA; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Velculescu VE; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Fijneman RJA; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. |
| المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Mar 01; Vol. 29 (5), pp. 899-909. |
| نوع المنشور: | Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Denville, NJ : The Association, c1995- |
| مواضيع طبية MeSH: | Cell-Free Nucleic Acids*/genetics , Circulating Tumor DNA*/genetics , Colonic Neoplasms* , Rectal Neoplasms*, Humans ; Biomarkers, Tumor/genetics ; DNA, Neoplasm/genetics ; High-Throughput Nucleotide Sequencing ; Mutation ; Prospective Studies |
| مستخلص: | Purpose: Circulating tumor DNA (ctDNA) has the potential to guide therapy selection and monitor treatment response in patients with metastatic cancer. However, germline and clonal hematopoiesis-associated alterations can confound identification of tumor-specific mutations in cell-free DNA (cfDNA), often requiring additional sequencing of tumor tissue. The current study assessed whether ctDNA-based treatment response monitoring could be performed in a tumor tissue-independent manner by combining ultra-deep targeted sequencing analyses of cfDNA with patient-matched white blood cell (WBC)-derived DNA. Experimental Design: In total, 183 cfDNA and 49 WBC samples, along with 28 tissue samples, from 52 patients with metastatic colorectal cancer participating in the prospective phase III CAIRO5 clinical trial were analyzed using an ultra-deep targeted sequencing liquid biopsy assay. Results: The combined cfDNA and WBC analysis prevented false-positives due to germline or hematopoietic variants in 40% of patients. Patient-matched tumor tissue sequencing did not provide additional information. Longitudinal analyses of ctDNA were more predictive of overall survival than standard-of-care radiological response evaluation. ctDNA mutations related to primary or acquired resistance to panitumumab were identified in 42% of patients. Conclusions: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens. (©2022 The Authors; Published by the American Association for Cancer Research.) |
| References: | Sci Transl Med. 2018 Sep 5;10(457):. (PMID: 30185652) Clin Cancer Res. 2021 Oct 15;27(20):5586-5594. (PMID: 33926918) J Mol Diagn. 2021 Oct;23(10):1324-1333. (PMID: 34314880) PLoS Med. 2021 May 3;18(5):e1003620. (PMID: 33939694) Nature. 2019 Jun;570(7761):385-389. (PMID: 31142840) Sci Transl Med. 2014 Feb 19;6(224):224ra24. (PMID: 24553385) Nature. 2012 Jun 28;486(7404):532-6. (PMID: 22722830) J Pathol Clin Res. 2021 May;7(3):203-208. (PMID: 33635598) N Engl J Med. 2014 Dec 25;371(26):2488-98. (PMID: 25426837) JAMA Oncol. 2017 Feb 01;3(2):194-201. (PMID: 27722750) Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774) Clin Cancer Res. 2020 Aug 1;26(15):4010-4017. (PMID: 32220893) JAMA. 2021 Feb 16;325(7):669-685. (PMID: 33591350) Clin Cancer Res. 2019 Dec 1;25(23):6899-6908. (PMID: 31263029) Clin Cancer Res. 2015 Aug 1;21(15):3377-83. (PMID: 26071484) Ann Oncol. 2019 Mar 1;30(3):358-359. (PMID: 30649226) JCO Precis Oncol. 2021 Feb 12;5:. (PMID: 34250420) Nat Commun. 2020 Jan 27;11(1):525. (PMID: 31988276) JCO Precis Oncol. 2017 Jul;2017:. (PMID: 28890946) J Clin Oncol. 2008 Apr 1;26(10):1626-34. (PMID: 18316791) World J Gastroenterol. 2016 Jul 28;22(28):6345-61. (PMID: 27605871) Oncologist. 2021 Nov;26(11):e1971-e1981. (PMID: 34286887) Cancer Discov. 2014 Jun;4(6):650-61. (PMID: 24801577) Cancer Discov. 2018 Feb;8(2):164-173. (PMID: 29196463) JAMA Oncol. 2019 Dec 1;5(12):1710-1717. (PMID: 31621801) Sci Rep. 2019 Nov 22;9(1):17358. (PMID: 31758080) Cancer Discov. 2014 Nov;4(11):1269-80. (PMID: 25293556) Cancer Res. 2019 Mar 15;79(6):1204-1213. (PMID: 30573519) Br J Radiol. 2016;89(1061):20151030. (PMID: 26864054) Clin Cancer Res. 2017 Sep 15;23(18):5437-5445. (PMID: 28600478) Int J Cancer. 2018 Apr 1;142(7):1418-1426. (PMID: 29134647) Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9. (PMID: 25190710) Sci Rep. 2019 Aug 8;9(1):11542. (PMID: 31395942) Br J Cancer. 2022 Aug;127(3):394-407. (PMID: 35264786) N Engl J Med. 2018 Nov 01;379(18):1754-1765. (PMID: 30380390) Sci Transl Med. 2017 Aug 16;9(403):. (PMID: 28814544) Nature. 2015 Oct 8;526(7572):263-7. (PMID: 26416732) J Mol Med (Berl). 2014 Jul;92(7):709-22. (PMID: 24811491) JCO Precis Oncol. 2021 Nov;5:1540-1553. (PMID: 34994642) Clin Biochem. 2021 Jun;92:46-53. (PMID: 33737000) Mol Cancer Ther. 2018 Oct;17(10):2238-2247. (PMID: 29997152) Nat Med. 2014 Dec;20(12):1472-8. (PMID: 25326804) BMC Cancer. 2015 May 06;15:365. (PMID: 25943574) Lancet Oncol. 2011 Jun;12(6):594-603. (PMID: 21163703) Cancer Res. 2019 Mar 15;79(6):1214-1225. (PMID: 30541742) Cancers (Basel). 2016 Aug 31;8(9):. (PMID: 27589804) J Mol Diagn. 2020 Dec;22(12):1430-1437. (PMID: 32961317) Nat Med. 2016 Nov;22(11):1342-1350. (PMID: 27694933) Nat Med. 2022 Aug;28(8):1612-1618. (PMID: 35915157) Nat Med. 2019 Dec;25(12):1928-1937. (PMID: 31768066) N Engl J Med. 2013 Sep 12;369(11):1023-34. (PMID: 24024839) |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) 0 (Cell-Free Nucleic Acids) 0 (Circulating Tumor DNA) 0 (DNA, Neoplasm) |
| تواريخ الأحداث: | Date Created: 20221219 Date Completed: 20230310 Latest Revision: 20230330 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9975664 |
| DOI: | 10.1158/1078-0432.CCR-22-2538 |
| PMID: | 36534496 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-3265 |
|---|---|
| DOI: | 10.1158/1078-0432.CCR-22-2538 |